Market Access News | pharmaphorum

News

Abecma delay gives Carvykti a chance to catch up

Bristol-Myers Squibb and partner 2seventy bio are facing a delay in their attempt to bring BCMA-directed CAR-T therapy Abecma to the US market as an earlier-line therapy f

News

Generics group says VPAG may lead to shortages

Among those celebrating today’s agreement on a voluntary rebate scheme for branded medicines in the UK, there are dissenting voices, including a group representing manufac

News

'Landmark' deal reached on UK voluntary rebate scheme

After months of wrangling, an agreement has finally been reached on a successor to the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), the system of reve

News

After FDA no, Almirall’s eczema drug gets EU okay

The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in

News

FDA’s Janet Woodcock will step down early next year

Janet Woodcock will bring a career at the FDA spanning almost four decades to a close next year, retiring from her current role as principal deputy commissioner of the reg

News

AZ first to AKT finish line, but FDA clears narrow label

AstraZeneca has claimed FDA approval for its first-in-class pan-AKT inhibitor capivasertib, getting a green light for the drug as a treatment for breast cancer, but with a

Abecma delay gives Carvykti a chance to catch up

Generics group says VPAG may lead to shortages

'Landmark' deal reached on UK voluntary rebate scheme

After FDA no, Almirall’s eczema drug gets EU okay

FDA’s Janet Woodcock will step down early next year

AZ first to AKT finish line, but FDA clears narrow label

J&J's oral IL-23 drug backed for psoriasis in EU

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks